TSX gains after CPI shows US inflation rose 3%
Todd Watanabe, CEO of Arcutis Biotherapeutics Inc (NASDAQ:ARQT), sold 10,129 shares of common stock on September 8 and 9, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The sales, totaling $177,628, were executed at prices ranging from $17.5179 to $17.5376. The transactions come as ARQT trades near its 52-week high of $18.15, having delivered an impressive 61.64% return over the past year. According to InvestingPro analysis, the stock appears slightly undervalued at current levels.
On September 8, Watanabe sold 9,625 shares. Following this, on September 9, he sold an additional 504 shares. The transactions were executed under a pre-arranged 10b5-1 trading plan adopted on June 14, 2024, with a plan end date of September 30, 2025. The $2.12 billion market cap company maintains impressive gross profit margins of 89.1%. For deeper insights into ARQT’s valuation and 12+ additional ProTips, visit InvestingPro.
Following the reported transactions, Watanabe directly owns 891,440 shares of Arcutis Biotherapeutics. He also indirectly owns shares through various trusts and an LLC: 25,410 shares are held by The John Franklin Watanabe Trust, 25,410 shares by The Anderson Prest Watanabe Irrevocable Trust, 57,358 shares by Watanabe Ventures, LLC, and 124,956 shares by The Watanabe 2016 Irrevocable Trust.
In other recent news, Arcutis Biotherapeutics reported its earnings for the second quarter of 2025, exceeding both earnings per share (EPS) and revenue forecasts. The company posted an EPS of -$0.13, outperforming the projected -$0.17, and reported revenue of $81.5 million, surpassing expectations by 11.26%. Additionally, Arcutis has submitted a supplemental New Drug Application to the U.S. Food and Drug Administration to expand the use of its ZORYVE cream for treating plaque psoriasis in children as young as 2 years old. If approved, ZORYVE would be the first topical PDE4 inhibitor indicated for plaque psoriasis in this age group. In related news, Palvella Therapeutics has appointed David W. Osborne, Ph.D., as Chief Innovation Officer. Dr. Osborne, a co-founder of Arcutis Biotherapeutics, brings over 25 years of experience in developing topical therapies, including ZORYVE cream and foam. These developments highlight the ongoing advancements and strategic appointments within the biopharmaceutical industry.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.